Neimeth International Pharmaceuticals Q3 2026 Board Update

Neimeth International Pharmaceuticals Plc has disclosed the outcome of its Board of Directors meeting held on Tuesday, 27th October 2026, via a corporate action filing submitted to the Nigerian Exchange Limited on the same date.

At the meeting, the board approved the company's Unaudited Financial Statements for the third quarter ended 30th September 2026, referred to in the filing as the 2026 Q3 UFS. The company stated that these financial statements will be filed with the NGX on or before 30th October 2026.

The filing also addresses the closed period that had been previously announced by the company. Under that restriction, insiders and connected persons are prohibited from trading in Neimeth's shares. The company confirmed that this closed period will remain in effect until twenty-four hours after the 2026 Q3 UFS is released to the public.

The notice was signed by Chinenye S. Adekanmbi, the company's Secretary. No financial figures were disclosed in this particular filing, as the unaudited statements themselves are yet to be published. The actual Q3 financials are expected to become available to the public no later than 30th October 2026, after which the insider trading restriction will be lifted within the specified timeframe.